IL-33 Reporter HEK 293 Cells
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
HEK-Blue™ IL-33 Cells Human IL-33 Reporter Cells |
Show product |
3-7 x 10e6 cells |
hkb-hil33
|
|
IL-33 Reporter Cells
IL-33 signaling in HEK-Blue™ IL-33 Cells
HEK-Blue™ IL-33 cells are designed to detect bioactive interleukin-33 (IL-33) by monitoring the activation of the NF-κB and AP-1 pathways. IL-33 is a pro-inflammatory cytokine that shares structural and functional characteristics with the IL-1 cytokine family. It binds and signals through the IL-1RL1/ IL-1R accessory protein (IL-1RAcP) receptor activating NF-κB and MAP kinases.
More details on Interleukin-33
Cell line description:
HEK-Blue™ IL-33 cells were generated by stable transfection of human embryonic kidney HEK293-derived cells with the human IL1RL1 gene. In addition, the TNF-α and the IL-1β responses have been blocked.
Therefore, HEK-Blue™ IL-33 cells respond specifically to IL-33. These cells express an NF-κB/AP-1- inducible SEAP reporter gene.
The binding of human IL-33 to the heterodimeric IL-1RL1/ IL-1RAcP on the surface of these cells triggers a signaling cascade leading to the activation of NF-κB and the subsequent production of SEAP.
Levels of SEAP in the supernatant can be easily determined with QUANTI-Blue™ Solution.
Features of HEK-Blue™ IL-33 cells:
- Fully functional IL-33 signaling pathway
- Do not respond to human TNF-α
- Do not respond to human IL-1β
- Readily assessable SEAP reporter activity
- Functionally tested and guaranteed mycoplasma-free
Applications of HEK-Blue™ IL-33 cells:
- Detection of human IL-33
- Screening of anti-IL-33 antibodies
Specifications
Antibiotic resistance: blasticidin, hygromycin B, Zeocin®
Growth medium: DMEM, 4.5 g/l glucose, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™
Guaranteed mycoplasma-free
Specificity: Detects human IL-33
Detection range: 0.5 - 100 ng/ml
This product is covered by a Limited Use License (See Terms and Conditions).
Back to the topContents
- 1 vial containing 3-7 x 106 cells
- 2 x 1 ml of HEK-Blue™ Selection (250x concentrate)
- 1 ml of Normocin™ (50 mg/ml)
- 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)
Shipped on dry ice (Europe, USA, Canada and some areas in Asia)
Details
Interleukin-33 (IL-33; also known as IL-1F11, DVS22, NF-HEV)) is a member of the IL-1/Toll-like receptor cytokine superfamily, a group of cytokines that play important roles in host defense, immune regulation, and inflammation [1, 2].
IL-33 is constitutively expressed in lymphoid tissues, epithelial cells, fibroblasts, mucosal tissues, tumor cells, and vascular tissues [3]. It plays a central role in type 2 innate and adaptive immunity and inflammation, modulating Th2, ILC2 and M2 macrophage responses [2]. It is involved in responses to type 2 infections (e.g. parasites), tissue repair, as well as harmful allergic responses (e.g. asthma) [2].
IL-33 mediates its biological effects through the IL-1R4 receptor (also known as ST2, IL1RL1, IL-33R) and the IL-1R3 accessory protein (also known as IL-1RAcP or IL-1RAP) [2, 4, 5].
Upon ligand binding, IL-1Rs dimerize through their Toll/interleukin-1 resistance (TIR) domains to recruit the MyD88 adaptor protein, which then couples to IL-1R-associated kinases (IRAKs) and tumor necrosis factor receptor-associated factor 6 (TRAF6). This leads to the activation of key transcription factors, including NF-KB, AP-1, and IRFs [2, 4].
IL-33 can function both as a traditional cytokine and as a nuclear factor regulating gene transcription. Following pro-inflammatory stimulation, IL-33 can induce Th2-biased immune responses, such as the production of IL-4, IL-5 and IL-13 [6]. In addition, as IL-33 is constitutively expressed in endothelial and epithelial cells, it can act as an endogenous danger signal, or damage-associated molecular pattern (DAMP; also called alarmins), in response to tissue damage [7, 8].
IL-33 has emerged as a key regulatory cytokine in barrier tissues, making it an important target for inhibition therapy in autoimmune diseases such as inflammatory bowel disease (IBD), rhumatoid arthgritis (RA), asthma, and allergies.
1. Arend W. et al., 2008. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev. 223:20-38.
2. Mantovani, A., et al., 2019. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 50(4): p. 778-795.
3. Catalan-Dibene, J. et al., 2018. Interleukin 30 to Interleukin 40. J Interferon Cytokine Res. 38(10):423-439.
4. Teufel, L.U., et al., 2022. IL-1 family cytokines as drivers and inhibitors of trained immunity. Cytokine. 150: p. 155773.
5. Gaballa, J.M., et al., 2024. International nomenclature guidelines for the IL-1 family of cytokines and receptors. Nature Immunology. 25(4): p. 581-582.
6. Schiering C. et al., 2014. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 513(7519):564-8.
7. Cayrol C. & Girard JP., 2014. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol. 31-7.
8. Oboki K. et al., 2011. IL-33 and airway inflammation. Allergy Asthma Immunol Res. 3(2): 81–88.